keyword
MENU ▼
Read by QxMD icon Read
search

Cancer pain, neuropathy, pain

keyword
https://www.readbyqxmd.com/read/28104535/immune-mediated-processes-implicated-in-chemotherapy-induced-peripheral-neuropathy
#1
REVIEW
Justin G Lees, Preet G S Makker, Ryan S Tonkin, Munawwar Abdulla, Susanna B Park, David Goldstein, Gila Moalem-Taylor
Chemotherapy-induced peripheral neuropathy (CIPN) and associated neuropathic pain are challenging complications of cancer treatment. Many of the major classes of chemotherapeutics can cause neurotoxicity and significantly modulate the immune system. There is ongoing investigation regarding whether reciprocal crosstalk between the nervous and immune systems occurs and, indeed, contributes to neuropathic pain during treatment with chemotherapeutics. An emerging concept is that neuroinflammation is one of the major mechanisms underlying CIPN...
January 16, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28088201/anti-allodynic-effect-of-buja-in-a-rat-model-of-oxaliplatin-induced-peripheral-neuropathy-via-spinal-astrocytes-and-pro-inflammatory-cytokines-suppression
#2
Yongjae Jung, Ji Hwan Lee, Woojin Kim, Sang Hyub Yoon, Sun Kwang Kim
BACKGROUND: Oxaliplatin, a widely used anticancer drug against metastatic colorectal cancer, can induce acute peripheral neuropathy, which is characterized by cold and mechanical allodynia. Activation of glial cells (e.g. astrocytes and microglia) and increase of pro-inflammatory cytokines (e.g. IL-1β and TNF-α) in the spinal cord play a crucial role in the pathogenesis of neuropathic pain. Our previous study demonstrated that Gyejigachulbu-Tang (GBT), a herbal complex formula, alleviates oxaliplatin-induced neuropathic pain in rats by suppressing spinal glial activation...
January 14, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/28069154/the-assessment-and-management-of-chemotherapy-related-toxicities-in-patients-with-breast-cancer-colorectal-cancer-and-hodgkin-s-and-non-hodgkin-s-lymphomas-a-scoping-review
#3
Patricia Fox, Andrew Darley, Eileen Furlong, Christine Miaskowski, Elisabeth Patiraki, Jo Armes, Emma Ream, Constantina Papadopoulou, Lisa McCann, Nora Kearney, Roma Maguire
PURPOSE: The purpose of the eSMART (Electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology) study is to evaluate the use of mobile phone technology to manage chemotherapy-related toxicities (CRTs) in people with breast cancer (BC), colorectal cancer (CRC), Hodgkin's lymphoma (HL), and non-Hodgkin lymphoma (NHL)) across multiple European sites. One key objective was to review the published and grey literature on assessment and management of CRTs among patients receiving primary chemotherapy for BC, CRC, HL, and NHL to ensure that ASyMS remained evidence-based and reflected current and local practice...
February 2017: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/28068938/acupuncture-combined-with-methylcobalamin-for-the-treatment-of-chemotherapy-induced-peripheral-neuropathy-in-patients-with-multiple-myeloma
#4
Xiaoyan Han, Lijuan Wang, Hongfei Shi, Gaofeng Zheng, Jingsong He, Wenjun Wu, Jimin Shi, Guoqing Wei, Weiyan Zheng, Jie Sun, He Huang, Zhen Cai
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) seriously affects the quality of life of patients with multiple myeloma (MM) as well as the response rate to chemotherapy. Acupuncture has a potential role in the treatment of CIPN, but at present there have been no randomized clinical research studies to analyze the effectiveness of acupuncture for the treatment of CIPN, particularly in MM patients. METHODS: The MM patients (104 individuals) who met the inclusion criteria were randomly assigned into a solely methylcobalamin therapy group (500 μg intramuscular methylcobalamin injections every other day for 20 days; ten injections) followed by 2 months of 500 μg oral methylcobalamin administration, three times per day) and an acupuncture combined with methylcobalamin (Met + Acu) group (methylcobalamin used the same way as above accompanied by three cycles of acupuncture)...
January 9, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28065184/long-term-outcomes-in-the-management-of-painful-diabetic-neuropathy
#5
Lauren M Mai, A John Clark, Allan S Gordon, Mary E Lynch, Pat K Morley-Forster, Howard Nathan, Catherine Smyth, Larry W Stitt, Cory Toth, Mark A Ware, Dwight E Moulin
BACKGROUND: Painful diabetic neuropathy (PDN) is a frequent complication of diabetes mellitus. Current treatment recommendations are based on short-term trials, generally of ≤3 months' duration. Limited data are available on the long-term outcomes of this chronic disease. The objective of this study was to determine the long-term clinical effectiveness of the management of chronic PDN at tertiary pain centres. METHODS: From a prospective observational cohort study of patients with chronic neuropathic non-cancer pain recruited from seven Canadian tertiary pain centres, 60 patients diagnosed with PDN were identified for analysis...
January 9, 2017: Canadian Journal of Neurological Sciences. le Journal Canadien des Sciences Neurologiques
https://www.readbyqxmd.com/read/28063866/chemotherapy-induced-neuropathy-in-cancer-survivors
#6
Christine Miaskowski, Judy Mastick, Steven M Paul, Kimberly Topp, Betty Smoot, Gary Abrams, Lee-May Chen, Kord M Kober, Yvette P Conley, Margaret Chesney, Kay Bolla, Grace Mausisa, Melissa Mazor, Melisa Wong, Mark Schumacher, Jon D Levine
CONTEXT: Evidence suggests that chemotherapy-induced neuropathy (CIN) is a significant problem for cancer survivors. However, a detailed phenotypic characterization of CIN in cancer survivors is not available. OBJECTIVES: To evaluate between group differences in demographic and clinical characteristics, as well as in measures of sensation, function, and postural control, in a sample of cancer survivors who received a platinum and/or a taxane-based CTX regimen and did (n=426) and did not (n=197) develop CIN...
January 4, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28041630/the-analgesic-effect-of-orexin-a-in-a-murine-model-of-chemotherapy-induced-neuropathic-pain
#7
Satoshi Toyama, Naohito Shimoyama, Megumi Shimoyama
Orexins are neuropeptides that are localized to neurons in the lateral and dorsal hypothalamus but its receptors are distributed to many different regions of the central nervous system. Orexins are implicated in a variety of physiological functions including sleep regulation, energy homeostats, and stress reactions. Furthermore, orexins administered exogenously have been shown to have analgesic effects in animal models. A type of intractable pain in patients is pain due to chemotherapy-induced peripheral neuropathy (CIPN)...
December 24, 2016: Neuropeptides
https://www.readbyqxmd.com/read/28032218/symptom-clusters-during-palliative-chemotherapy-and-their-influence-on-functioning-and-quality-of-life
#8
Sun Young Rha, Jiyeon Lee
INTRODUCTION: Symptom management in patients undergoing palliative chemotherapy is challenging, as patients may suffer from cancer symptoms as well as symptoms related to chemotherapy. Symptom clusters are interrelated symptoms occurring simultaneously that exert a negative impact on survival. Identification of symptom clusters and effective symptom management for patients receiving palliative chemotherapy is crucial. OBJECTIVES: The purpose of this study was to identify symptom clusters among cancer patients undergoing palliative chemotherapy and examine the relationship between symptom clusters and functioning and quality of life (QOL) in these patients...
December 28, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28012171/mir-15b-mediates-oxaliplatin-induced-chronic-neuropathic-pain-through-bace1-downregulation
#9
Naomi Ito, Atsushi Sakai, Noriko Miyake, Motoyo Maruyama, Hirotoshi Iwasaki, Koichi Miyake, Takashi Okada, Atsuhiro Sakamoto, Hidenori Suzuki
BACKGROUND AND PURPOSE: Although oxaliplatin is an effective anti-cancer platinum compound, it can cause painful chronic neuropathy, and its molecular mechanisms remain poorly understood. MicroRNAs are small non-coding RNAs that negatively regulate gene expression in a sequence-specific manner. Although microRNAs have been increasingly recognised as important modulators in a variety of pain conditions, their involvement in chemotherapy-induced neuropathic pain is unknown. EXPERIMENTAL APPROACH: Oxaliplatin-induced chronic neuropathic pain was induced in rats by intraperitoneal oxaliplatin injections (2 mg kg(-1) ) for 5 consecutive days...
December 23, 2016: British Journal of Pharmacology
https://www.readbyqxmd.com/read/28004441/referred-symptom-from-myofascial-pain-syndrome-one-of-the-most-important-causes-of-sensory-disturbance-in-breast-cancer-patients-using-taxanes
#10
E J Ko, J Y Jeon, W Kim, J Y Hong, Y G Yi
The aim of this retrospective study was to evaluate common causes of upper extremity sensory disturbance in breast cancer patients. Breast cancer patients who received surgery and taxane chemotherapy (CTx) with upper extremity sensory disturbance that began after CTx were included. With comprehensive clinical history, physical examination and electrodiagnostic results, diagnosis for each patient was made. Fifty-two patients were included: 23 (44.2%) were diagnosed with chemotherapy-induced peripheral neuropathy (CIPN), 7 (13...
December 22, 2016: European Journal of Cancer Care
https://www.readbyqxmd.com/read/27994987/preventative-and-therapeutic-effects-of-a-gaba-transporter-1-inhibitor-administered-systemically-in-a-mouse-model-of-paclitaxel-induced-neuropathic-pain
#11
Willias Masocha, Subramanian S Parvathy
BACKGROUND: There is a dearth of drugs to manage a dose-limiting painful peripheral neuropathy induced by paclitaxel in some patients during the treatment of cancer. Gamma-aminobutyric acid transporter-1 (GAT-1) whose expression is increased in the brain and spinal cord during paclitaxel-induced neuropathic pain (PINP) might be a potential therapeutic target for managing PINP. Thus, our aim was to evaluate if systemic administration of a GAT-1 inhibitor ameliorates PINP. METHODS: The reaction latency to thermal stimuli (hot plate test; at 55 °C) and cold stimuli (cold plate test; at 4 °C) of female BALB/c mice was recorded before and after intraperitoneal treatment with paclitaxel, its vehicle, and/or a selective GAT-1 inhibitor NO-711...
2016: PeerJ
https://www.readbyqxmd.com/read/27980107/niclosamide-inhibits-oxaliplatin-neurotoxicity-while-improving-colorectal-cancer-therapeutic-response
#12
Olivier Cerles, Evelyne Benoit, Christiane Chéreau, Sandrine Chouzenoux, Florence Morin, Marie-Anne Guillaumot, Romain Coriat, Niloufar Kavian, Thomas Loussier, Pietro Santulli, Louis Marcellin, Nathaniel E B Saidu, Bernard Weill, Frederic Batteux, Carole Nicco
Neuropathic pain is a limiting-factor of platinum-based chemotherapies. We sought to investigate the neuroprotective potential of niclosamide in peripheral neuropathies induced by oxaliplatin. Normal neuron-like and cancer cells were treated in vitro with oxaliplatin associated or not with an inhibitor of STAT3 and NF-кB, niclosamide. Cell production of reactive oxygen species and viability were measured by 2',7'-dichlorodihydrofluorescein diacetate and crystal violet. Peripheral neuropathies were induced in mice by oxaliplatin with or without niclosamide...
December 15, 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27884691/aapt-diagnostic-criteria-for-chronic-cancer-pain-conditions
#13
REVIEW
Judith A Paice, Matt Mulvey, Michael Bennett, Patrick M Dougherty, John T Farrar, Patrick W Mantyh, Christine Miaskowski, Brian Schmidt, Thomas J Smith
: Chronic cancer pain is a serious complication of malignancy or its treatment. Currently, no comprehensive, universally accepted cancer pain classification system exists. Clarity in classification of common cancer pain syndromes would improve clinical assessment and management. Moreover, an evidence-based taxonomy would enhance cancer pain research efforts by providing consistent diagnostic criteria, ensuring comparability across clinical trials. As part of a collaborative effort between the Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks (ACTTION) and the American Pain Society (APS), the ACTTION-APS Pain Taxonomy initiative worked to develop the characteristics of an optimal diagnostic system...
November 21, 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/27854104/new-practical-approaches-to-chemotherapy-induced-neuropathic-pain-prevention-assessment-and-treatment
#14
REVIEW
Neil Majithia, Charles L Loprinzi, Thomas J Smith
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most disabling and demoralizing problems that arise for cancer survivors. When investigating symptoms of numbness, tingling, or pain in the extremities, it is critical to determine whether the problem is neuropathic, somatic, or mixed. If the diagnosis is CIPN, it is important to weigh the potential benefits and harms of possible treatment options, and to devise an evidence-based multimodality treatment program. Such programs may include mixtures of opioid and nonopioid adjunctive medications, based on evidence from CIPN trials, and also extrapolation from trials in patients with other neuropathic pain syndromes-although such extrapolating must be done with caution, since other syndromes sometimes respond to agents that CIPN does not respond to...
November 15, 2016: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/27846661/-physical-therapy-for-chemotherapy-induced-peripheral-neuropathy-in-pediatric-oncology
#15
M Jung, N Rein, B Fuchs
Background: Chemotherapy-induced peripheral neuropathy is a frequent side-effect of drugs that are used in the treatment of cancer. Affected individuals can suffer from motor, sensory or autonomy nerve damage. Further medication is used for the treatment of CIPN which can cause further side-effects. Patients should be offered physical therapy treatment to relieve the symptoms. Objective: The aim of this article is to give an overview of available literature investigating physical therapy in CIPN in pediatric oncology...
November 2016: Klinische Pädiatrie
https://www.readbyqxmd.com/read/27844290/potentiation-of-paclitaxel-induced-pain-syndrome-in-mice-by-angiotensin-i-converting-enzyme-inhibition-and-involvement-of-kinins
#16
Indiara Brusco, Cássia Regina Silva, Gabriela Trevisan, Camila de Campos Velho Gewehr, Flávia Karine Rigo, Lidia La Rocca Tamiozzo, Mateus Fortes Rossato, Raquel Tonello, Gerusa Duarte Dalmolin, Daniela de Almeida Cabrini, Marcus Vinícius Gomez, Juliano Ferreira, Sara Marchesan Oliveira
Paclitaxel is a chemotherapeutic agent used to treat solid tumours. However, it causes an acute and neuropathic pain syndrome that limits its use. Among the mechanisms involved in neuropathic pain caused by paclitaxel is activation of kinin receptors. Angiotensin converting enzyme (ACE) inhibitors can enhance kinin receptor signalling. The goal of this study was to evaluate the role of kinins on paclitaxel-associated acute pain syndromes (P-APS) and the effect of ACE inhibition on P-APS and paclitaxel-associated chronic peripheral neuropathy (P-CPN) in mice...
November 14, 2016: Molecular Neurobiology
https://www.readbyqxmd.com/read/27811127/collet-sicard-syndrome-a-rare-but-important-presentation-of-internal-jugular-vein-thrombosis
#17
Shermyn Neo, Kim En Lee
We describe a rare neurological presentation of internal jugular vein thrombosis induced by central venous catheter placement in a patient with cancer. A 71-year-old man gave a 3-week history of dysphagia and dysarthria with left-sided neck pain and headache. He was receiving chemotherapy for appendiceal adenocarcinoma. On examination, he had left 9th-12th cranial neuropathies, manifesting as voice hoarseness, decreased palatal movement, absent gag reflex, weakness of scapular elevation and left-sided tongue wasting...
January 2017: Practical Neurology
https://www.readbyqxmd.com/read/27803912/efficacy-of-japanese-traditional-kampo-medicine-for-treating-chemotherapy-induced-peripheral-neuropathy-a-retrospective-case-series-study
#18
Yumiko Kimata, Keiko Ogawa, Hideki Okamoto, Atsushi Chino, Takao Namiki
AIM: To investigate Japanese traditional (Kampo) medicine's effectiveness on cancer chemotherapy-induced peripheral neuropathy (CIPN), we carried out this retrospective study. METHODS: By searching our outpatient database of 3154 patients who consulted our outpatient clinic of Japanese-Oriental (Kampo) Medicine at Chiba University Hospital from November 2005 to December 2010, a total of 281 patients diagnosed with cancer were identified. Twenty-four patients out of the 281 patients identified met the following three conditions and were eligible for further investigation of the effectiveness of Kampo treatment: At least one course of cancer chemotherapy had been administered; numbness and pain appeared after the chemotherapy; and CIPN was diagnosed before they were given Kampo treatment...
October 16, 2016: World Journal of Clinical Cases
https://www.readbyqxmd.com/read/27798187/cd8-t-cells-and-endogenous-il-10-are-required-for-resolution-of-chemotherapy-induced-neuropathic-pain
#19
Karen Krukowski, Niels Eijkelkamp, Geoffroy Laumet, C Erik Hack, Yan Li, Patrick M Dougherty, Cobi J Heijnen, Annemieke Kavelaars
: Chemotherapy-induced peripheral neuropathy (CIPN), characterized by pain and numbness in hands and feet, is a common side effect of cancer treatment. In most patients, symptoms of CIPN subside after treatment completion. However, in a substantial subgroup, CIPN persists long into survivorship. Impairment in pain resolution pathways may explain persistent CIPN. We investigated the contribution of T cells and endogenous interleukin (IL)-10 to resolution of CIPN. Paclitaxel-induced mechanical allodynia was prolonged in T-cell-deficient (Rag1(-/-)) mice compared with wild-type (WT) mice...
October 26, 2016: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/27789344/behavioral-and-electromyographic-assessment-of-oxaliplatin-induced-motor-dysfunctions-evidence-for-a-therapeutic-effect-of-allopregnanolone
#20
O Taleb, F Bouzobra, H Tekin-Pala, L Meyer, A G Mensah-Nyagan, C Patte-Mensah
The antineoplastic oxaliplatin (OXAL) is pivotal for metastatic cancer treatments. However, OXAL evokes sensory and motor side-effects including pain, muscle weakness, motor nerve fiber dysfunctions/neuropathies that significantly impact patients' lives. Therefore, preclinical investigations are struggling to characterize effective analgesics against OXAL-induced painful/sensory symptoms but surprisingly, OXAL-evoked motor dysfunctions received little attention although these neurological symptoms are also disabling for patients...
October 24, 2016: Behavioural Brain Research
keyword
keyword
76402
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"